Centene (NYSE: CNC) Surges 14% on Q1 Strength and Medicaid Momentum

Centene Corporation (NYSE: CNC) delivered a sharp rally, climbing 13.95% to $49.57, as the managed care giant posted Q1 earnings that exceeded expectations and signaled accelerating momentum in its core Medicaid business despite near-term margin pressures.

The stock surge reflects investor relief on two fronts: robust revenue expansion of 23.2% year-over-year and evidence that the company is navigating the Medicaid unwinding cycle more effectively than feared. While profitability remains under pressure—the company posted a negative 3.79% profit margin—the forward P/E of 12.46 indicates the market is discounting near-term headwinds and pricing in a recovery path.

By the Numbers

• Revenue growth: 23.2% year-over-year
• Gross margin: 10.47%
• Operating margin: -1.88%
• Forward P/E: 12.46x

What Drove the Results

Centene's Q1 outperformance stems from higher-than-expected enrollment retention in Medicaid plans as states complete the unwinding of emergency coverage expansions. The 23.2% revenue growth reflects both organic member growth and the integration of prior-year acquisitions, particularly expanded presence in key state programs.

Margin compression, reflected in the negative 3.79% profit margin, is a deliberate trade-off. The company has prioritized member acquisition and retention during the unwinding period by investing in care management and limiting rate increases. Management views this as a short-term sacrifice to build market share and entrench relationships with state health agencies—a positioning that could yield higher margins once unwinding stabilizes in the second half of 2026.

Wall Street View

The 13.95% jump signals analyst consensus that Centene has successfully de-risked the Medicaid unwinding narrative. With a forward P/E of just 12.46, the stock is trading at a significant discount to historical averages, even accounting for margin headwinds. The market appears to be positioning for a "show me" quarter later in 2026 when management can prove that enrollment stabilization translates into margin recovery.

Investor Takeaway

Centene's rally reflects a successful near-term inflection point in one of the managed care industry's biggest uncertainties. For value investors, the combination of 23.2% revenue growth, a compressed forward multiple, and clarity on the Medicaid unwinding timeline creates a compelling entry point. The key risk is that margin recovery takes longer than anticipated—watch Q2 and Q3 for signs of stabilization in operating margins. If the company can return to single-digit positive margins by year-end 2026, the stock has additional upside from current levels.